版本:
中国

BRIEF-Miragen Therapeutics receives orphan-drug designation for MRG-106

March 31 Miragen Therapeutics Inc:

* Miragen Therapeutics receives orphan-drug designation for MRG-106 for the treatment of mycosis fungoides Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐